Product NewsAvacta Announces Distribution Agreement with ABCAM plcby Avacta Group plcGlobal distribution agreement with ABCAM plc to sell Avacta’s SARS-CoV-2 research ELISA Affimer reagents
NewsAvacta Launches SARS-CoV-2 BAMS Research Testby Avacta Group plcAffimer-based research assay launched alongside performance data published by Bruker
NewsAvacta to Launch SARS-CoV-2 ELISA Laboratory Testby Avacta Group plcAvacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus
NewsAvacta Provides Update on COVID-19 Antigen Diagnostic Test Development with Adeptrixby Avacta Group plcHighly specific prototype test detects the virus spike protein at clinically relevant concentrations
Product NewsAvacta Group Plc Forms COVID-19 Antigen Diagnostic Collaboration with Adeptrixby Avacta Group plcSecond partnership to exploit the recently generated Affimer binders to the SARS-COV-2 virus in a high throughput COVID-19 antigen test
Product NewsAvacta and Cytiva Ahead of Schedule on COVID-19 Rapid Testby Avacta Group plcAvacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership
Product NewsAvacta and Cytiva Collaborating on COVID-19 Rapid Testby Avacta Group plcPartnership to develop and manufacture a rapid test for the COVID-19 coronavirus infection for population screening
Avacta Group Plc Announces Successful Outcome of “Gene Delivery” Collaboration with FIT Biotechby Avacta Group plcSustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits